Respected funds and partners related to SciNova, as well as comrades and friends who support the development of SciNova

Happy New Year to everyone!

In 2022, the Chuangrui related fund team and Dianshi Chuangjian team overcame the interference of the epidemic and did four aspects of work: first, post investment management work, second, research upgrading work, third, clinical validation work, and fourth, international resource construction.

1、 In terms of post investment management and exit of funds: In 2022, the single year exit amount of some of the main funds of SciNova reached 60% of the total principal amount of the fund in 2022, and some single project funds reached 200% of the principal amount in that year, achieving accelerated recovery and return of funds from these fund LPs. In the middle of 2022, Kaishi Biotechnology successfully passed the meeting, and from 2022 to 2023, multiple companies were applying for listing. In 2023, Chongrui and Dianshi Chuangjian will have a more resolute and in-depth post investment management to create nominal value and achieve real cash flow for LPs.

2、 In terms of research work: In 2022, the SciNova Medical team achieved a systematic upgrade of research work. Nearly 20 research and investment colleagues track over 15 international innovation signal sources and over 20 domestic innovation signal sources, covering approximately 100 key innovation directions in the medical field. In early 2023, participating in global peer exchanges, the team has basically verified that it can achieve important innovation signals such as the progress of innovation approval by the US FDA and the latest global scientific research progress reported by MIT, nature, science, and other reports. Within one month, it can enter the research tracking vision of Chuanrui and Dianshi Chuangjian.

3、 In terms of clinical validation, the SciNova team has achieved clinical trend communication, joint analysis projects, and joint transformation projects with Xiangya Medical College, Chongqing Medical University, Dongfang Hospital, and Huashan Hospital. In mid-2023, we will continue to deepen and expand cooperation in research and transformation.

4、 In terms of international resources, SciNova resumed investment cooperation and exchanges with Cleveland Hospital in early 2023, and further strengthened cooperation with Harvard Medical School. In 2023, there will be over 10 domestic landing medical projects initiated by top Chinese scientists. From the second half of 2022, the Chuangrui team observed market reversal signals and released multiple observations and predictions on the improvement signals of the primary and secondary markets starting from June 2022. They actively prepared and reserved a large number of partners and high-quality projects for the work in 2023.

In 2023, SciNova and related fund teams will focus on "medical innovation with clinical needs As the main keyword, actively participate in and learn from medical investment conferences and industry conferences such as JPMorgan Conference, BFC, RESI, ASCO, RSNA, Arterial Network Top 100 Evaluation, strengthen one's own learning and growth, track global innovative medical development trends, search for first-class innovation projects, contact senior leaders, recruit innovative talents, promote innovative concepts, and promote the development of medical innovation enterprises. We hope to receive the support of all leaders and colleagues as always Guide!

On the occasion of the arrival of the Spring Festival in the Year of the Rabbit, the representative of the Chuang Rui Investment Management Team and all colleagues of Chuang Rui sincerely wish you good luck in life, great career prospects, healthy and smooth New Year, and happy family!

Wishing you a happy New Year again!

Tang Haofu/Zhang Minglong/Cong Risheng/Liu Xiaoxia/Wang Yuqiao and all employees of SciNova